...
首页> 外文期刊>Journal of oncology pharmacy practice: official publication of the International Society of Oncology Pharmacy Practitioners >Use of prescription and nonprescription medications and supplements by cancer patients during chemotherapy: questionnaire validation.
【24h】

Use of prescription and nonprescription medications and supplements by cancer patients during chemotherapy: questionnaire validation.

机译:癌症患者在化疗期间使用处方药和非处方药以及补品:问卷验证。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

BACKGROUND: Cancer patients take medications for coexisting disease and self-medicate with over-the-counter drugs (OTCs). A complete analysis of the use of prescription drugs, OTCs, and supplements during cancer treatment has never been done. METHODS: The study developed and validated a self-administered questionnaire on the use of concomitant medications by patients undergoing treatment with chemotherapy. The questionnaire listed 510 prescription medications, OTCs, and supplements (including vitamins, minerals, and herbs). Fifty-two subjects completed the questionnaire while visiting the infusion clinic to receive chemotherapy. On a subsequent visit the subjects brought their medications to the clinic and a pharmacist reviewed their completed questionnaire. RESULTS: Ninety-six percent of the subjects reported taking prescription medications within 3 days prior to chemotherapy, 71% reported taking OTCs and 69% reported use of supplements. The subjects took an average of 5.5 (range 0-13) prescription drugs, 2.2 (0-20) OTCs, and 1.9 (0-11) supplements. Twenty-one drugs were each taken by at least 10% of the subjects. Acetaminophen was taken by 59.6% of the subjects. One subject reported taking five acetaminophen-containing drugs. The questionnaire's sensitivity was 92.0%, specificity 99.9%. CONCLUSION: Within 3 days prior to chemotherapy, subjects took an average of 9.6 concomitant medications, many of which alter drug metabolism and or disposition. In clinical trials, multivariate analysis of all concomitant medications could add to clinically relevant data to identify drug interactions that negate or potentiate the efficacy of cancer treatment regimens. In some instances, apparent resistance of tumors to chemotherapy may be the result of drug interactions.
机译:背景:癌症患者服用与疾病共存的药物,并与非处方药(OTC)一起自我治疗。从未对癌症治疗期间处方药,非处方药和补品的使用情况进行过全面分析。方法:该研究制定并验证了一项自行管理的问卷,该问卷针对接受化疗的患者使用伴随药物的情况。调查表列出了510种处方药,非处方药和补品(包括维生素,矿物质和草药)。 52名受试者在前往输液诊所接受化疗时填写了调查表。在随后的访问中,受试者将药物带到诊所,药剂师检查了他们完整的问卷。结果:百分之九十六的受试者报告在化疗前3天内服用处方药,百分之71的受试者报告服用OTC,百分之69的受试者报告使用补充剂。受试者平均服用5.5(范围为0-13)处方药,2.2(0-20)类非处方药和1.9(0-11)补品。至少有10%的受试者服用了21种药物。对乙酰氨基酚占59.6%。一名受试者报告服用了五种含对乙酰氨基酚的药物。问卷的敏感性为92.0%,特异性为99.9%。结论:在化疗前3天内,受试者平均服用9.6种伴随药物,其中许多药物会改变药物的代谢和/或处置。在临床试验中,所有伴随用药的多变量分析可能会增加临床相关数据,以识别否定或增强癌症治疗方案疗效的药物相互作用。在某些情况下,肿瘤对化疗的明显耐药性可能是药物相互作用的结果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号